Effects of semelil (ANGIPARS™) on diabetic peripheral neuropathy: A randomized, double-blind placebo-controlled clinical trial

DARU, Journal of Pharmaceutical Sciences

Volumn 19, Issue 1, 2011, Pages 65-70

  Bakhshayeshi, S ^a   Madani, SP ^b   Hemmatabadi, M ^a   Heshmat, R ^a   Larijani, B ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Diabetes mellitus; Peripheral neuropathy

Indexed keywords

ANGIPARS; HERBACEOUS AGENT; PLACEBO; SEMELIL; UNCLASSIFIED DRUG;

ACTION POTENTIAL; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; LABORATORY TEST; LATENT PERIOD; MALE; NERVE CONDUCTION; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PERCEPTIVE THRESHOLD; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT DURATION; ULNAR NERVE; VIBRATION; VISUAL ANALOG SCALE;

EID: 79953267624     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Unger J, Cole BE. Recognition and management of diabetic neuropathy. Primary Care: Clinics in Office Practice, 2007; 34:887-913.
2. Boulton AJM, Malik RA, Arezzo JC, Sosenko JM. Diabetic somatic neuropathies Diabetes Care, 2004; 27: 1458-1486.
3. Aaron I Vini k. Advances in Diabetes for the Millennium: New Treatments for Diabetic Neuropathies. MedGenMed, 2004; 6: 13.
4. Boulton JMA, Vinik IA, Arezzo CJ, Bril V, Feldman LE, Freeman R. Diabetic Neuropathies. Diabetes Care, 2005; 28:956-962.
5. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. How far have we come? Diabetes care, 2008;31:255-261.
6. Pop-Busuil R, Sima A, Stevens M. Diabetic neuropathy and oxidative stress. Diabetes Metab Res Rev, 2006; 22: 257-273
7. Abdollahi M, Farzamfar B, Salari P, Khorram Khorshid HR, Larijani B, Farhadi M, Madani SH. Evaluation of acute and sub-chronic toxicity of Semelil (ANGIPARS™), a new phytotherapeutic drug for wound healing in rodents. DARU, 2008; 16:7-14.
8. Khorram Khorshid HR, Sadeghi B, Heshmat R, Abdollahi M, Salari P, Farzamfar B, Madani SH. In vivo and in vitro genotoxicity studies of Semelil (ANGIPARS™). DARU, 2008; 16: 20-24.
9. Masoompour SM, Bagheri MH, Borhani Haghighi A, Novitsky YA, Sadeghi B, Gharibdoust F, Larijani B, Ranjbar Omrani G. Effect of ANGIPARS™, a new herbal drug on diabetic foot ulcer: A phase 2 clinical study. DARU, 2008; 16: 31-34.
10. Bahrami A, Kamali K, Ali-Asgharzadeh A, Hosseini P, Heshmat R, Khorram Khorram HR, Gharibdoust F, Madani SH, Larijani B. Clinical application of oral form of ANGIPARS™ and in combination with topical form as a new treatment for diabetic foot ulcers: A randomized clinical trial.DARU, 2008; 16: 41-48.
11. Ebrahimi M, Bakhshayeshi S, Heshmat R, Shahbazi S, Aala M, Peimani M, Khushechin G, Mohajeri Tehrani MR, Shojaeefard A, Kamali K, Azimaraghi O, Larijani B. Post marketing surveillance on safety and effectiveness of ANGIPARS™ in treatment of diabetic foot ulcers. DARU, 2009; 17:45-49.
12. Plesca-Manea L, Parvu AE, Parvu M, Taamas M, Buia R, Puia M. Effects of Melilotus officinalis on acute inflammation. Phytotherapy research, 2002; 16: 316-319.
13. Molina-Jiménez MF, Sánchez-Reus MI, Cáscales M, Andrés D, Benedí J. Effect of fraxetin on antioxidant defense and stress proteins in human neuroblastoma cell model of rotenone neurotoxicity. Comparative study with myricetin and N-acetylcysteine. Toxicol Appl Pharmacol, 2005; 15; 209:214-225.
14. Forouzandeh F, Aziz Ahari A, Abolhasani F, Larijani B. Comparison of different screening tests for detecting diabetic foot neuropathy.Acta Neurol Scand, 2005; 112: 409-413.
15. Lunetta M, Le Moli R, Grasso G, Sangiorgio L. A simplified diagnostic test for ambulatory screening of peripheral diabetic neuropathy. Diabetes Research and Clinical Practice, 1998; 39: 165-172.
16. Feldman EL, Stevens MJ, Thomas PK, Brown MB, Canal N, Greene DA. Apractical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care, 1994;17:1281-1289.
17. Langley GB, Sheppeard H. The visual analogue scale: Its use in pain measurement Rheumatol Int, 1985; 5:145-148.
18. Hemmatabadi M, Abdollahi M, Bakhshayeshi S, Heshmat R, Baeeri M, Azimaraghi O, Larijani B. Benefits of Semelil (ANGIPARS™) on oxidant-antioxidant balance in diabetic patients; A randomized, double-blind placebo controlled clinical trial. DARU, 2010; 17: 50-55.